0.475
-0.03 (-5.00%)
Previous Close | 0.500 |
Open | 0.475 |
Volume | 4,725 |
Avg. Volume (3M) | 78,252 |
Market Cap | 68,117,848 |
Price / Sales | 10.91 |
Price / Book | 2.40 |
52 Weeks Range | |
Earnings Date | 20 Feb 2024 - 26 Feb 2024 |
Profit Margin | -129.74% |
Operating Margin (TTM) | -87.70% |
Diluted EPS (TTM) | -0.110 |
Quarterly Revenue Growth (YOY) | -21.40% |
Total Debt/Equity (MRQ) | 2.00% |
Current Ratio (MRQ) | 10.04 |
Operating Cash Flow (TTM) | -10.12 M |
Levered Free Cash Flow (TTM) | -10.88 M |
Return on Assets (TTM) | -19.69% |
Return on Equity (TTM) | -34.34% |
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (AU) | Mixed | Mixed |
Diagnostics & Research (Global) | Mixed | Mixed | |
Stock | GENETICSIG FPO | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | 3.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.0 |
Average | 0.25 |
Genetic Signatures Ltd is a specialist molecular diagnostics company, specialising in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are primarily based in Australia, with sales and support teams in the UK, Germany, and the United States. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Small Value |
% Held by Insiders | 27.59% |
% Held by Institutions | 44.19% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |